Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus ILUVIEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus ILUVIEN.
BETAMETHASONE SODIUM PHOSPHATE vs ILUVIEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to suppress inflammation, immune response, and reduce capillary permeability.
Fluocinolone acetonide, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. It also inhibits cytokine production and endothelial cell adhesion molecule expression.
0.5-9 mg/day IV or IM in divided doses every 12-24 hours; acute conditions may require 4-8 mg IV initially.
Intravitreal implant containing 0.19 mg fluocinolone acetonide, designed to release drug over approximately 36 months. Administered as a single injection into the vitreous cavity of the eye.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours (plasma); biological half-life (HPA axis suppression): 24-36 hours.
Intravitreal terminal half-life of fluocinolone acetonide from the Iluvien implant is approximately 30 months (range 18-36 months), providing sustained release over 36 months in the vitreous cavity.
Renal: 90-95% as inactive metabolites; biliary/fecal: <5%.
Fluocinolone acetonide is primarily eliminated via hepatic metabolism and subsequent fecal/biliary excretion. Approximately 50-70% of a dose is excreted in feces as metabolites, with less than 20% recovered in urine as unchanged drug or metabolites.
Category D/X
Category C
Corticosteroid
Corticosteroid